Testing effectiveness (Phase 2)Not Yet RecruitingNCT06282536
What this trial is testing
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Who this might be right for
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 20